Simple blood tests to inform lung cancer treatment strategies regardless of stage
Personalized therapies have transformed treatment options for non-small cell lung cancer but require comprehensive biomarker testing to determine a patient’s eligibility and likelihood of a positive response. Conventional tests assessing tumor mutations can take weeks to receive results, leading to difficult decisions on treatment initiation1. Additionally, high PD-L1 expression alone does not inform selection of guideline recommended immunotherapy regimens, with or without chemotherapy. IQLung™ tests provide best-in-class turnaround time to evaluate the presence of actionable mutations in circulating tumor RNA and DNA (ctRNA/ctDNA) and novel information about a patient’s immune response to lung cancer.

Expedite personalized treatment decisions

with results in 3 business days*

Empower care teams

with a testing strategy for any stage of non-small cell lung cancer (NSCLC)2

Improve overall survival

For patients with high PD-L1 expression eligible for immunotherapy regimens2,3

Biodesix Access Program

Biodesix is committed to making our tests available to all patients. Our Biodesix Access Program covers all billing needs in-house.

For additional information on coverage and reimbursement.
Click Here
GeneStrat® test

A targeted test that identifies actionable tumor mutations in early-stage NSCLC patients


The GeneStrat test helps identify the presence of mutations in the EGFR, ALK, KRAS, and BRAF genes that inform eligibility for neoadjuvant targeted therapy, adjuvant targeted therapy, or clinical trial enrollment.

97% Tissue Concordance4

High agreement with tissue

100% Specificity4

No false positives

91% Sensitivity4

Majority of mutations identified
Can be ordered multiple times per patient when medically necessary, such as for recurrent cancer.
GeneStrat NGS® test

A broad 52 gene panel that identifies actionable tumor mutations in advanced stage NSCLC patients


The GeneStrat NGS test helps identify the presence of actionable mutations in advanced stage NSCLC that inform eligibility for targeted therapy or clinical trial enrollment.

No tissue required

Blood-based testing conserves tissue samples
icon

Identifies guideline recommended mutations

To drive key clinical decisions
Supports multi-disciplinary collaboration by providing results in 3 business days*.
VeriStrat® test

Novel predictive and prognostic host immune classifier for any stage of NSCLC


The VeriStrat test helps identify patients that would benefit from enhanced surveillance or combination therapies.

Predictive and prognostic of outcomes independent of ECOG performance status, mutation status, PD-L1 expression, treatment choice, and line of therapy.
VeriStrat Good
Implies the tumor directed immunity is not suppressed. Patients with a VeriStrat Good classification are likely to benefit from standard of care therapies, including immunotherapy regimens2,3.
VeriStrat Poor
Implies the tumor directed immunity is compromised. Patients with a VeriStrat Poor classification being considered for immune checkpoint inhibitor (ICI) therapy may benefit from the addition of chemotherapy2,3.
Predictive and prognostic of outcomes independent of ECOG performance status, mutation status, PD-L1 expression, treatment choice, and line of therapy.
Download an example test report
For a full list of publications that support IQLung Testing
Click Here

Interested in learning more?

Contact us

1Bowling, M. et al. ECU clinical experience study: Utilization of liquid biopsy to determine time to diagnosis and treatment in NSCLC. Journal of Clinical Oncology, 2018; 36:15_suppl, abstract e18519. 2Rich P, Mitchell RB, Schaefer E, et al. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. Journal for ImmunoTherapy of Cancer 2021;9:e002989. 3Leal, T.A. et al. Prognostic Performance of Proteomic Testing in Advanced Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis. Current Medical Research and Opinion, 2020 4Mellert, H. et al. Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma. The Journal of Molecular Diagnostics, 2017; May;19(3):404-416. *3 business days represents the average turnaround time for testing, individual test turnaround times may vary.